Prognostic PET 18F-FDG uptake imaging features are associated with major oncogenomic alterations in patients with resected non-small cell lung cancer

Cancer Research

Volumn 72, Issue 15, 2012, Pages 3725-3734

  Nair, Viswam S ^a   Gevaert, Olivier ^a   Davidzon, Guido ^a   Napel, Sandy ^a   Graves, Edward E ^a   Hoang, Chuong D ^a,b   Shrager, Joseph B ^a   Quon, Andrew ^a   Rubin, Daniel L ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MINICHROMOSOME MAINTENANCE PROTEIN 6; SEPRASE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; FEMALE; FIBROBLAST ACTIVATION PROTEIN ALPHA GENE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ANTIGEN 6 COMPLEX LOCUS E GENE; MALE; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 6 GENE; ONCOGENE; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RING FINGER PROTEIN 149 GENE; TUMOR VOLUME; BIOLOGICAL MODEL; CLINICAL TRIAL; COHORT ANALYSIS; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; GENOMIC INSTABILITY; HUMAN GENOME; LUNG RESECTION; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; SCINTISCANNING; SURVIVAL; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; GENOMIC INSTABILITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ONCOGENES; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865005045     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3943     Document Type: Article

References (47)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552-9.
3. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
4. Nair VS, Barnett PG, Ananth L, Gould MK. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 2010;137:1150-6.
5. Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010;5:612-9.
6. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-92.
7. Gould MK, Sanders GD, Barnett PG, Rydzak CE, Maclean CC, McClellan MB, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003;138:724-35.
8. Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J Clin Oncol 1998;16:2113-25.
9. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
10. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 2009;19:17-24.
11. Frezza C, Gottlieb E. Mitochondria in cancer: not just innocent bystanders. Semin Cancer Biol 2009;19:4-11.
12. Shanmugam M, McBrayer SK, Rosen ST. Targeting the Warburg effect in hematological malignancies: from PET to therapy. Curr Opin Oncol 2009;21:531-6.
13. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007;26:223-4.
14. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
15. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3.
16. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008;452:181-6.
17. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010;329:1492-9.
18. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011;480:118-22.
19. Gevaert O, Xu J, Hoang C, Leung A, Xu Y, Quon A, et al. Identification of prognostic imaging biomarkers for non-small cell lung cancer by leveraging public gene expression microarray data. Radiology. 2012.
20. Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008;14:7397-404.
21. Graves EE, Quon A, Loo BW Jr. RT-Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat 2007;6:111-21.
22. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;74:1335-41.
23. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002;99:6567-72.
24. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
25. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997;16:385-95.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
28. Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, Lu TH, et al. GeneSigDB-a curated database of gene expression signatures. Nucleic Acids Res 2010;38(Database issue):D716-25.
29. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
30. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 2011;39(Database issue):D691-7.
31. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
32. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011;71:6921-5.
33. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, et al. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. J Nucl Med 2010;51:543-50.
34. Palaskas NJ, Larson SM, Schultz N, Komisopoulou E, Wong J, Rohle D, et al. 18F-fluorodeoxy-glucose positron emission tomography (18FDG-PET) marks MYC-overexpressing human basal-like breast cancers. Cancer Res 2011;71:5164-74.
35. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
36. Warburg O. On the origin of cancer cells. Science 1956;123: 309-14.
37. Robey RB, Hay N. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 2009;19:25-31.
38. Dang CV. Enigmatic MYC conducts an unfolding systems biology symphony. Genes Cancer 2010;1:526-31.
39. Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? Cell Cycle 2010;9:3884-6.
40. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010;70:859-62.
41. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45:1519-27.
42. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45.
43. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-63.
44. Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET. J Nucl Med 2010;51:268-76.
45. Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS, Lammertsma AA, et al. Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 2009;50:1646-54.
46. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
47. Casali C, Cucca M, Rossi G, Barbieri F, Iacuzio L, Bagni B, et al. The variation of prognostic significance of maximum standardized uptake value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung Cancer 2010;69:187-93.